A phase IIa , double-blind, placebo-controlled dose-ranging study of KHK4563
Phase 2
- Conditions
- Asthma
- Registration Number
- JPRN-jRCT2080221534
- Lead Sponsor
- Kyowa Hakko Kirin Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Uncontrolled asthma requiring medium-dose or high-dose ICS plus LABA
- History of => 2 but =< 6 documented asthma exacerbations in the 12 months that required use of a systemic corticosteroid burst
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method